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ABSTRACT
Objective Pregnancy in women with aortic coarctation 
(CoA) has an estimated moderately increased risk 
(mWHO II–III) of adverse cardiovascular, obstetric 
or fetal events, but prospective data to validate this 
risk classification are scarce. We examined pregnancy 
outcomes and identified associations with adverse 
outcomes.
Methods Pregnancies in women with CoA were 
selected from the worldwide prospective Registry of 
Pregnancy and Cardiac Disease (ROPAC, n=303 out 
of 5739), part of the European Society of Cardiology 
EURObservational Research Programme. The frequency 
of and associations with major adverse cardiac events 
(MACE) and hypertensive disorders (pregnancy- induced 
hypertension, (pre- )eclampsia or haemolysis, elevated 
liver enzymes and low platelets syndrome) were 
analysed.
Results Of 303 pregnancies (mean age 30 years, 
pregnancy duration 39 weeks), 9.6% involved unrepaired 
CoA and 27.1% were in women with pre- existing 
hypertension. No maternal deaths or aortic dissections 
occurred. MACE occurred in 13 pregnancies (4.3%), of 
which 10 cases were of heart failure (3.3%). Univariable 
associations with MACE included prepregnancy clinical 
signs of heart failure (OR 31.8, 95% CI 6.8 to 147.7), 
left ventricular ejection fraction <40% (OR 10.4, 95% CI 
1.8 to 59.5), New York Heart Association class >1 (OR 
11.4, 95% CI 3.6 to 36.3) and cardiac medication use 
(OR 4.9, 95% CI 1.3 to 18.3). Hypertensive disorders of 
pregnancy occurred in 16 (5.3%), cardiac medication 
use being their only predictor (OR 3.2, 95% CI 1.1 to 
9.6). Premature births were 9.1%, caesarean section 
was performed in 49.7% of pregnancies. Of 4 neonatal 
deaths, 3 were after spontaneous extreme preterm birth.
Conclusions The ROPAC data show low MACE and 
hypertensive disorder rates during pregnancy in women 
with CoA, suggesting pregnancy to be more safe and 
better tolerated than previously appreciated.
INTRODUCTION
Contemporary cohorts of patients with repaired 
aortic coarctation (CoA) have good long- term 
survival but relatively high cardiac complication 
rates, including re- coarctation in 34%, aortic aneu-
rysms in 18%, hypertension in 32% and 13- fold 
increased risk for ischaemic stroke as compared 
with controls without congenital heart disease.1–4 
Pregnant women with repaired CoA are currently 
classified as mWHO II–III in the modified WHO 
classification.5 mWHO II–III represents an inter-
mediate risk of maternal mortality and a moderate- 
to- severe risk of morbidity, corresponding with a 
cardiac event rate of 10%–19% during pregnancy. 
Women with unrepaired severe CoA are considered 
to be mWHO class IV.5 Despite these cautionary 
numbers, the reported rates of complications during 
pregnancy vary widely.6–12 The mWHO classifica-
tion is based on expert opinion and the previous 
literature, which consists of several retrospective 
studies, a retrospective review of a large administra-
tive database (Nationwide Inpatient Sample, USA) 
and one prospective cohort study of 49 patients 
with CoA.6–12 These studies used different end 
points and a variable proportion of women with 
unrepaired CoA were included.6–12
Also, surgical and catheter interventions have 
improved, meaning that historical studies may not 
reflect current experience. Consequently, there is 
a need for a large, prospective contemporaneous 
study with clearly defined inclusion criteria and 
end points, to allow us to counsel the increasing 
number of women who are surviving their surgical 
correction and considering whether to become 
pregnant. In this manuscript, we examine maternal 
and fetal outcomes in women with CoA from the 
worldwide prospective Registry Of Pregnancy And 
Cardiac Disease (ROPAC), and identify associations 
with adverse cardiac outcome and hypertensive 
disorders.
METHODS
The ROPAC is a worldwide prospective registry 
of pregnancies in women with structural heart 
disease. It was initiated in 2007 by the European 
Society of Cardiology as part of the EURObser-
vational Research Programme. Further details on 
study protocol and study design were published 
previously.13 Informed consent was obtained when 
required by the local ethics committee of partici-
pating centres. Patients were prospectively included 
from January 2008 to January 2018, in addition to 
retrospective inclusions from 2007. A total of 5739 
pregnancies were included from 138 participating 
centres in 53 countries.
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Aortic coarctation
From the total ROPAC cohort of 5739 pregnancies, 303 (5%) 
pregnancies in women with CoA (mean age 30 years) were iden-
tified and included in the study. Both repaired and unrepaired 
CoA were included. Residual CoA was not specified as a variable 
in the ROPAC case report form and therefore was not available. 
Aortic dilatation was defined as an aortic diameter >40 mm.
Data collection and definitions
Data were collected by the local investigator for each partici-
pating centre, using patient record files. Baseline patients’ char-
acteristics before pregnancy included age, parity, primary cardiac 
diagnosis and concomitant cardiac or valvular disease, prior 
interventions, cardiovascular risk factors, New York Heart Asso-
ciation (NYHA) functional classification, cardiac medication and 
if available, echocardiographic parameters. The International 
Monetary Fund classification was used to define a participating 
country as emerging or advanced.
Maternal cardiac end points
Cardiac end points were maternal cardiac death, hospitalisa-
tion for cardiac reasons, heart failure during pregnancy or 
within 6 months post partum, atrial fibrillation/flutter, ventric-
ular tachyarrhythmias, endocarditis, thromboembolic events, 
aortic dissection and acute coronary syndrome. A major adverse 
cardiac event (MACE) was defined as a composite outcome of 
these end points, excluding hospital admission.
Obstetric and fetal end points
Obstetric and fetal end points were pregnancy- induced hyper-
tension, (pre- )eclampsia or haemolysis, elevated liver enzymes 
and low platelets (HELLP) syndrome, postpartum haemor-
rhage, (emergency) caesarean section, fetal mortality >24 weeks 
gestation, neonatal mortality <6 months, intrauterine growth 
restriction, preterm delivery (<37 weeks gestational age), low 
Apgar score (<7) and birth weight, which was classified as low 
birth weight when <2.500 g. Hypertensive disorders of preg-
nancy were defined as pregnancy- induced hypertension, (pre- )
eclampsia or HELLP syndrome and according to the 2018 Inter-
national Society for the Study of Hypertension in Pregnancy 
statement.14
Statistical analysis
Baseline characteristics and outcomes were compared between 
women with prior hypertension and without prior hypertension, 
as well as between repaired and unrepaired CoA and between 
women with and without bicuspid aortic valve (BAV). Addition-
ally, the outcomes of MACE and hypertensive disorders were 
evaluated after dividing the cohort in three risk profiles: (1) no 
prior hypertension and repaired CoA, (2) prior hypertension 
or unrepaired CoA and (3) both prior hypertension and unre-
paired CoA. Normality of continuous data was examined using 
QQ- plots and subsequently data are presented as mean and SD, 
or as median and IQR. Differences between the groups were 
calculated using Student’s t- tests, or Mann- Whitney U tests for 
skewed data. Categorical data are presented as percentages and 
compared using χ2 tests.
Univariate logistic regression was used to identify associations 
with MACE or hypertensive disorders. The number of events 
(n=13) did not allow for multivariate analysis. Missing data 
were handled with multiple imputation. A two- sided p value 
<0.05 was considered to be statistically significant. There were 
no corrections for multiple testing performed. All analyses and 
imputations were performed using IBM SPSS Statistics V.25.0 
(IBM).
Patient and public involvement
This research was done without patient involvement.
RESULTS
Baseline characteristics of the 303 pregnancies in women with 
CoA are presented in table 1. Pre- existing hypertension was 
reported in 81 (27.1%) of pregnancies and in 127 (41.9%) 
cardiac medication was used before pregnancy. Twenty- nine 
(9.6%) pregnancies were in women with unrepaired CoA. None 
of the women had Turner’s syndrome or Shone complex.
Baseline characteristics of women with unrepaired CoA and 
women with BAV are described in online supplemental table S1 
and S2. Prepregnancy characteristics for unrepaired CoA were 
comparable to the patients with repaired CoA. Women with BAV 
more often had prepregnancy aortic dilatation (8.1% vs 0.6%, 
p=0.001) and aortic valve stenosis (21.1% vs 3.9%, p<0.001), 
compared with women without BAV.
Women in emerging countries were more likely to have 
prepregnancy signs of heart failure (12.7% vs 0%, p<0.001) 
and to be in NYHA class >1 (25.4% vs 7.5%, p<0.001). They 
did not have more concomitant cardiac lesions compared with 
women in high- income countries (68.3% vs 64.2%, p=0.545), 
but more often had unrepaired CoA (20.6% vs 6.7%, p=0.001).
Cardiovascular outcomes
No maternal mortality occurred during pregnancy or up to 6 
months post partum (table 2). Overall, there were 23 (7.6%) 
hospital admissions, and 13 (4.3%) of those were due to MACE: 
heart failure in 10 (3.3%) and supraventricular arrhythmia in 3 
(1%) patients. MACE are described in further detail in table 3. 
Of 10 patients with heart failure, in 6 it was new- onset heart 
failure and 2 had prepregnancy left ventricular ejection fraction 
(LVEF) <40%. Only one had no additional cardiac lesions and in 
one CoA was unrepaired. Mean gestational age at development 
of heart failure was 25 (±8) weeks, with 5 patients in the second 
trimester, 5 patients in the third trimester and no postpartum 
cases. All three cases of supraventricular arrhythmia were in 
women with BAV. Out of the remaining 10 hospital admissions, 
8 patients were admitted for uncontrolled hypertension (without 
heart failure) and for 2 patients the reason for hospital admis-
sion was unknown. There were no peripartum complications, no 
aortic dissections, no cerebrovascular events and no therapeutic 
interventions performed during pregnancy.
Women with pre- existing hypertension had more hospital 
admissions for cardiac reasons compared with women without 
pre- existing hypertension (14.8% vs 5%, p=0.005), but there 
was no statistical difference in MACE (4.9% vs 4.1%, p=0.76). 
Admissions for uncontrolled hypertension were also more 
frequent than in women without pre- existing hypertension 
(6.2% vs 1.4%, p=0.022). Women with unrepaired CoA were 
also hospitalised more often than women with repaired CoA 
(20.7% vs 6.2%, p=0.005), predominantly for uncontrolled 
hypertension (13.8% vs 1.5%, p<0.001). There were no further 
differences in cardiovascular outcome (MACE 3.4% vs 4.4%; 
p=0.81). Despite aortic dilatation at baseline in 8.1% of women 
with BAV, there were no dissections and no difference in MACE 
between women with BAV and those without (3.3% vs 5%, 
p=0.461).
Maternal outcomes are summarised in figure 1 and table 2 
(comparison between pre- existing hypertension and no 
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pre- existing hypertension), online supplemental table S3 
(comparison between repaired and unrepaired CoA) and online 
supplemental table S4 (comparison between BAV and no BAV).
Obstetric and fetal outcomes
Hypertensive disorders of pregnancy were reported in 16 (5.3%) 
women, as pregnancy- induced hypertension and pre- eclampsia in 
8 (2.6%) pregnancies both. There were no cases of eclampsia or 
HELLP syndrome. Compared with women without pre- existing 
hypertension, women with pre- existing hypertension developed 
pre- eclampsia more often (0.9% vs 7.4%, p=0.002).
Caesarean section was performed in 49.7% of the CoA cohort, 
the majority of which were planned. Emergency caesarean 
sections were 10.2% and mainly for obstetric reasons, with 2.3% 
for cardiac reasons. Women with pre- existing hypertension were 
more likely to have an emergency caesarean section than women 
without pre- existing hypertension (16% vs 8.3%, p=0.049), but 
not more often for cardiac reasons. Women with unrepaired CoA 
Table 1 Baseline characteristics of the total coarctation cohort, women with pre- existing hypertension and women without pre- existing 
hypertension
Total cohort (n=303)
Pre- existing hypertension 
(n=81)
No pre- existing 
hypertension (n=222) P value
Demographics
  Age (mean, SD) 29.9 (5.3) 30.6 (5.4) 29.7 (5.3) 0.349
  Nulliparity (%) 155 (51.2) 45 (55.6) 109 (50) 0.393
  BMI (median, IQR) 23.3 (21.4–27.4) 24.1 (21.3–27.1) 23.0 (21.5–27.4) 0.953
  Emerging country (%) 63 (20.8) 19 (23.5) 43 (19.7) 0.479
Prepregnancy characteristics
  Current smoker (%) 9 (3.6) 3 (4.3) 6 (3.4) 0.735
  Diabetes mellitus (%) 6 (2) 0 (0) 5 (2.3) 0.172
  Atrial fibrillation (%) 1 (0.3) 0 (0) 1 (0.5) 0.541
  Signs of heart failure (%) 8 (2.6) 2 (2.5) 6 (2.8) 0.893
  LVEF <40% (%) 7 (2.3) 1 (1.2) 6 (2.8) 0.440
  Cardiac medication use before pregnancy (%) 127 (41.9) 60 (74.1) 66 (30.3) <0.001
   Beta- blocker 37 (12.2) 22 (27.2) 15 (6.9) <0.001
   ACE- inhibitor 9 (3.0) 7 (8.6) 2 (0.9) 0.001
   Calcium channel blocker 11 (3.6) 10 (12.3) 1 (0.5) <0.001
   Diuretics 2 (0.7) 1 (1.2) 1 (0.5) 0.464
  NYHA class I (%) 266 (87.8) 67 (82.5) 197 (90.4) 0.067
  NYHA class II (%) 31 (10.2) 13 (16) 17 (7.8) 0.035
  NYHA class III (%) 3 (1) 0 (0) 3 (1.4) 0.289
  NYHA class IV (%) 0 (0) 0 (0) 0 (0) n.a.
  Unrepaired coarctation (%) 29 (9.6) 19 (12.3) 18 (8.3) 0.281
  Surgery for recoarctation 41 (13.5%) 15 (18.5) 26 (11.9%) 0.141
  Bicuspid aortic valve (%) 123 (40.6) 30 (37) 92 (42.2) 0.419
  Ventricular septal defect (%) 37 (12.2) 5 (6.2) 32 (14.7) 0.047
  Persistent arterial duct (%) 17 (5.6) 3 (3.7) 14 (6.4) 0.367
  Aortic dilatation >40 mm (%) 11 (3.6) 3 (3.7) 8 (3.7) 0.989
  Valve replacement (%)* 15 (5) 3 (3.7) 12 (5.5) 0.526
  Aortic stenosis (%) 33 (10.9) 9 (11.1) 24 (11.0) 0.980
   Mild 20 (6.6) 4 (4.9) 16 (7.3)
   Moderate 13 (4.3) 5 (6.2) 8 (3.7)
   Severe 0 (0) 0 (0) 0 (0)
  Aortic regurgitation (%) 62 (17.3) 11 (15.6) 41 (18.8) 0.529
   Mild 40 (13.3) 8 (9.9) 32 (14.7)
   Moderate 12 (4) 3 (3.7) 9 (4.1)
   Severe 0 (0) 0 (0) 0 (0)
  Mitral stenosis (%) 4 (1.3) 0 (0) 4 (1.8) 0.219
  Mitral regurgitation (%) 52 (17.4) 15 (18.5) 36 (16.7) 0.796
   Mild 47 (15.7) 13 (16) 33 (15.3)
   Moderate 5 (1.7) 2 (2.5) 3 (1.4)
   Severe 0 (0) 0 (0) 0 (0)
  Echocardiogram data available 160 (53) – –
P values were calculated between the groups pre- existing hypertension and no pre- existing hypertension, using χ2 tests and Mann- Whitney U tests where appropriate. Bold 
values denote statistical significance at the p<0.05 level.
*13 aortic, 1 mitral and 1 tricuspid valve replacement.
BMI, body mass index (kg/m2); LVEF, left ventricular ejection fraction; n.a., not available; NYHA, New York Heart Association.
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underwent caesarean section more often compared with women 
with repaired CoA (71.4% vs 47.3%; p=0.015), but there was 
no difference in emergency caesarean sections or emergency 
caesarean sections for cardiac reasons.
Preterm delivery took place in 25 pregnancies (9.1%) at a 
median 35 (Q1–Q3 33–36) weeks of gestation, induced in 
6% and spontaneous in 3.1%. Intrauterine fetal demise >24 
weeks gestational age occurred in one case (0.3%) and neonatal 
mortality occurred in four cases (1.3%). Three of these deaths 
were after extremely premature delivery (gestational age between 
24 and 26 weeks) and were due to the resulting complications 
(cerebral haemorrhage; infection). One neonate, born at 38 
weeks gestational age, died of an unknown cause. Four (1.3%) 
newborns were diagnosed with non- cardiac congenital disease 
and 10 (3.3%) with congenital heart disease: 4 septal defects, 
2 aortic abnormalities, 2 univentricular hearts, 1 persistent 
ductus arteriosus and 1 pulmonary valve stenosis. There were 
no increased adverse fetal outcomes in the subgroup analyses for 
women with pre- existing hypertension, women with unrepaired 
CoA or women with BAV.
Obstetric and fetal outcomes are summarised in figure 1 
and table 2 (comparison between pre- existing hypertension 
and no pre- existing hypertension), online supplemental table 
S3 (comparison between repaired and unrepaired CoA) and 
online supplemental table S4 (comparison between BAV and 
no BAV).
Univariable associations with adverse outcomes
Univariable associations with MACE are displayed in figure 2. In 
the univariate analysis, emerging country (OR 4.9, 95% CI 1.6 
to 15.1), prepregnancy clinical signs of heart failure (OR 31.8, 
95% CI 6.8 to 147.7), left ventricular systolic function (LVEF) 
<40% (OR 10.4, 95% CI 1.8 to 59.5), NYHA class >1 (OR 
11.4, 95% CI 3.6 to 36.3) and cardiac medication use before 
pregnancy (OR 4.9, 95% CI 1.3 to 18.3) were characteristics 
predicting for MACE. Multivariate analysis was not possible due 
to the low number of events.
Univariate analysis for hypertensive disorders is displayed 
in figure 3. Only prepregnancy cardiac medication use was a 
statistically significant association (OR 3.2, 95% CI 1.1 to 9.6). 
Acetylsalicylic acid, commonly used as a prophylaxis in women 
with risk factors for pre- eclampsia, was used in 5.9% of all 
pregnancies between 14 and 36 weeks of gestation. It was not 
Table 2 Cardiovascular, obstetric and fetal outcome
Overall cohort (n=303)
Pre- existing hypertension 
(n=81)
No pre- existing 
hypertension (n=222) P value
Cardiovascular outcomes
  Maternal mortality (%) 0 (0) 0 (0) 0 (0) n.a.
  Hospital admission for cardiac reasons (%) 23 (7.6) 12 (14.8) 11 (5) 0.005
  Heart failure (%) 10 (3.3) 4 (4.9) 6 (2.8) 0.350
  Hospital admission for uncontrolled hypertension (%) 8 (2.6) 5 (6.2) 3 (1.4) 0.022
  Atrial fibrillation or flutter (%) 3 (1) 0 (0) 3 (1.4) 0.289
  Ventricular tachyarrhythmias (%) 0 (0) 0 (0) 0 (0) n.a.
  Endocarditis (%) 0 (0) 0 (0) 0 (0) n.a.
  Thromboembolic event (%) 0 (0) 0 (0) 0 (0) n.a.
  Aortic dissection (%) 0 (0) 0 (0) 0 (0) n.a.
  Acute coronary syndrome during pregnancy (%) 0 (0) 0 (0) 0 (0) n.a.
  Overall MACE (%) 13 (4.3) 4 (4.9) 9 (4.1) 0.760
Obstetric and fetal outcome
  Hypertensive disorders (%) 16 (5.3) 6 (7.4) 10 (4.6) 0.336
   Pregnancy- induced hypertension 8 (2.6) 0 (0) 8 (3.7) 0.081
   Pre- eclampsia 8 (2.6) 6 (7.4) 2 (0.9) 0.002
   Eclampsia or HELLP 0 (0) 0 (0) 0 (0) n.a.
  Postpartum haemorrhage (%) 5 (1.7) 1 (1.2) 4 (1.8) 0.719
  Caesarean section (%) 143 (49.7) 46 (58.2) 96 (46.6) 0.079
   Emergency caesarean section 31 (10.2) 13 (16) 18 (8.3) 0.049
   For cardiac reasons 7 (2.3) 3 (3.7) 4 (1.8) 0.342
  Fetal mortality >24 weeks (%) 1 (0.3) 0 (0) 1 (0.3) 0.387
  Neonatal mortality (%) 4 (1.3) 1 (1.2) 3 (1.4) 0.925
  IUGR (%) 12 (4.0) 6 (7.4) 6 (2.8) 0.068
  Preterm delivery (%) 25 (9.1) 7 (9) 18 (9.2) 0.947
  Low Apgar score <7 (%) 15 (5) 12 (5.5) 3 (3.7) 0.526
  Low birth weight <2.5 kg (%) 20 (6.6) 7 (8.6) 13 (6.0) 0.410
  Mean birth weight (SD) 3132.8 (566.1) 3024.2 (602.9) 3168.6 (552.8) 0.131
   With beta- blocker (n=56) 3018.8 (415.84) 3116.9 (374.4) 2920.6 (438.2) 0.077
   Without beta- blocker (n=133) 3180.9 (613.6) 2887.6 (828.1) 3230.1 (562.6) 0.024
P=0.072* P=0.204* P=0.008*
P values were calculated between the groups pre- existing hypertension and no pre- existing hypertension, using χ2 tests and unpaired t- tests where appropriate. Bold values 
denote statistical significance at the p<0.05 level.
*P values were calculated for birth weight between the groups with and without beta- blocker, using unpaired t- tests.
HELLP, haemolysis, elevated liver enzymes and low platelets syndrome; ; IUGR, intrauterine growth restriction; MACE, major adverse cardiac event; n.a., not available.
by copyright.
 on O
ctober 30, 2020 at E
rasm
us M
edical / X
51 4300.7802.430. P
rotected
http://heart.bm
j.com
/
H
eart: first published as 10.1136/heartjnl-2020-317513 on 29 O
ctober 2020. D
ow
nloaded from
 
5Ramlakhan KP, et al. Heart 2020;0:1–9. doi:10.1136/heartjnl-2020-317513
Congenital heart disease
associated with a lower incidence of hypertensive disorders (OR 
1.1, 95% CI 0.1 to 8.5).
In table 4, MACE and hypertensive disorders were tested 
against three different CoA profiles, but there were no differ-
ences in complication rates between the risk groups. MACE rate 
in emerging countries was significantly higher than in advanced 
countries (11.1% vs 2.5%, p=0.003), but no such difference 
existed for hypertensive disorders (6.3% vs 5%, p=0.670).
DISCUSSION
Based on 303 pregnancies in women with CoA from an inter-
national prospective registry, pregnancy seems to be safe and 
well- tolerated (figure 4). Cardiac event rates were lower than 
predicted according to the mWHO class risk stratification score. 
Another surprising finding was that hypertensive disorders of 
pregnancy were not more frequent than reported in the general 
population.
There were no maternal deaths in our cohort. One older 
report documents a disconcertingly high mortality rate of 9%.15 
Beauchesne et al9 describes one (1%) fatal dissection in a patient 
with Turner’s syndrome and twin pregnancy in a cohort of 118 
CoA pregnancies. More recent and contemporary studies report 
no maternal mortality,6 7 10 11 which is in line with our results. 
The largest cohort to date (n=697) from Krieger et al did not 
report a mortality rate, but instead includes maternal death in 
their composite adverse cardiovascular outcome (5%).12
The MACE rate of 4.3% is lower than the predicted 
10%–19% event rate for patients with a mWHO class II–III 
risk score.5 In particular, no cerebrovascular events nor aortic 
dissections occurred, which are recognised generally as the most 
feared complications in young adult patients with CoA,11 16 with 
pregnancy as a particular period of risk due to hormonally medi-
ated vessel wall weakness and increased thrombogenicity.17 18 
The MACE rates in this study are in line with recent literature. 
Krieger et al12 reports a 5% MACE rate, which is a similar event 
rate to our study. In a prospective observational cohort study of 
49 pregnancies, one major cardiovascular event (2%) occurred6 
and three other retrospective studies report zero major cardiac 
events.7 10 11 In our study, predictors of cardiac events were 
prepregnancy signs of heart failure, LVEF <40%, NYHA class 
>1 and cardiac medication use before pregnancy, along with 
living in an emerging country. Higher rates of adverse outcomes 
in women from emerging countries are likely explained by a 
higher rate of prepregnancy cardiac morbidity (higher rate of 
prepregnancy heart failure and higher functional class) and 
higher rates of unrepaired CoA. It is important to further eval-
uate specific risk factors determining pregnancy outcomes in 
women from emerging countries in order to elaborate strategies 
to improve these outcomes. Generally, our data indicate a profile 
of women with heart failure as the group most at risk for devel-
oping MACE. Considering the findings reported here and other 
recent literature, mWHO class II instead of II–III seems a more 
Table 3 Major adverse cardiac events in women with aortic coarctation
No Diagnosis Comorbidities Prepregnancy cardiac function GA at event
Medication and 
interventions
Timing and mode 
of delivery
1 HF VSD; pulmonary hypertension; aortic stenosis NYHA 3
LVEF >40%
Signs of HF: no
16 Sildenafil, bosentan, LMWH 34+2
CS
2 HF VSD; mitral stenosis NYHA 1
LVEF <40%
Signs of HF: no
23 Metoprolol, furosemide 34+4
CS
3 HF VSD; pulmonary valve stenosis, aortic 
regurgitation
NYHA 2
LVEF <40%
Signs of HF: no
33 Metoprolol, spironolacton 35+1
CS
4 HF PDA; BAV; aortic regurgitation NYHA 1
LVEF >40% signs HF: yes
33 Unknown 36+2
eCS
5 HF VSD; aortic stenosis and regurgitation; HT NYHA 2
LVEF >40%
Signs of HF: no
28 Unknown 35
CS
6 HF PDA NYHA 2
LVEF >40% signs HF: yes
13 Metoprolol 38+4
CS
7 HF None NYHA 2
LVEF >40% signs HF: yes
28 Unknown; diagnostic 
aortography
37+1
eCS
8 HF Unrepaired CoA; HT NYHA 1
LVEF >40%
Signs of HF: no
38 Unknown 39+5
CS
9 HF ASD; mitral regurgitation; HT NYHA 2
LVEF >40%
Signs of HF: no
26 Calcium channel blocker, 
methyldopa
38+5
Vaginal
10 HF Mitral regurgitation; HT NYHA 2
LVEF >40% signs HF: yes
16 Unknown 38
Vaginal
11 AF BAV; mitral regurgitation NYHA unknown
LVEF >40%
Signs of HF: no
Unknown Metoprolol Unknown
Vaginal
12 AF BAV; aortic stenosis and regurgitation; mitral 
stenosis and regurgitation; pulmonary valve 
regurgitation
NYHA 1
LVEF >40%
Signs of HF: no
16 Metoprolol, acetylsalicylic acid 39+6
Vaginal
13 AF BAV; aortic and mitral stenosis NYHA 1
LVEF >40%
Signs of HF: no
29 40+6
Vaginal
AF, atrial fibrillation; BAV, bicuspid aortic valve; CoA, aortic coarctation; (e)CS, (emergency) caesarean section; GA, gestational age (weeks+days if available); HF, heart failure; HT, hypertension; 
LMWH, low molecular weight heparin; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.
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appropriate risk assessment for pregnancies in asymptomatic 
women with CoA without signs of heart failure and/or normal or 
mildly reduced LVEF. Beside MACE, hospital admissions were 
most often because of uncontrolled hypertension, in particular in 
women with pre- existing hypertension or unrepaired CoA. Strict 
blood pressure control seems advisable in these pregnancies.
We found a surprisingly low number of hypertensive disor-
ders of pregnancy (5.3%) and comparable (low) rates of pre- 
eclampsia compared with the general population.19 20 These 
findings are in contrast to the previous studies, where hyperten-
sive disorders have been found as the most frequent complica-
tion of pregnancy in women with repaired CoA. Hypertensive 
disorder rates were reported between 14% and 20%,7 10 12 up 
to 30% if pre- existing hypertension is included in the definition 
of hypertensive outcomes.9 11 12 These differences may thus be 
partially explained by heterogeneous definitions of hyperten-
sive disorders during pregnancy. Given the focus on systemic 
hypertension in patients with repaired or unrepaired CoA, one 
may also speculate that the identification and treatment of pre- 
existing hypertension in women with CoA compared with unse-
lected pregnancy cohorts may have led to this surprisingly low 
number of hypertensive disorders of pregnancy. In this regard, 
it may be noteworthy the only previous prospective study found 
no difference in hypertensive disorder rates between women 
with CoA and healthy controls.6 In the study by Siegmund et al,6 
pregnancy- induced hypertension was found in 18% of pregnan-
cies and pre- eclampsia in 2% of pregnancies.
Pregnancy in unrepaired CoA is underreported and caregivers 
might be apprehensive about complications in this population, 
as demonstrated by the high caesarean section rate (71.4%). 
However, we did not find any increase in cardiac, obstetric or 
fetal adverse outcomes when compared with the repaired group. 
In the only study to describe pregnancy outcomes in unre-
paired CoA, no significant differences between the repaired and 
Figure 1 Cardiac events (top) and obstetric and fetal events (bottom) in women with aortic coarctation. Pre- existing hypertension versus no 
pre- existing hypertension (left) and unrepaired versus repaired (right). *P<0.05. There were no cases of ventricular tachyarrhythmia, endocarditis, 
thromboembolic events, acute coronary syndrome or aortic dissection. (e)CS, (emergency) caesarean section; MACE, major adverse cardiac event; PE, 
(pre- )eclampsia; PIH, pregnancy- induced hypertension; PPH, postpartum haemorrhage.
Figure 2 Univariate regression analysis, identifying predictors of major adverse cardiac events in pregnancy. Asterisk (*) denotes statistical 
significance. BMI, body mass index (kg/m2); CoA:, aortic coarctation.; HT, disorder: hypertensive disorder; LVEF, left ventricular ejection fraction; n.a., 
not available; NYHA, New York Heart Association.
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unrepaired group were found.9 In our cohort of women with 
unrepaired CoA, the severity of the coarctation was unknown 
and therefore our outcomes may not be applicable to women 
with severe unrepaired CoA.
The caesarean section rate of 49.7% is markedly higher than 
the globally observed rate of 21% and the recommended rate 
of 10%–15%,21 22 but similar to the 47% found in the total 
ROPAC cohort of all women with structural cardiac disease.23 
In unrepaired CoA, the caesarean section rate is even more 
pronounced (71%). This is not according to current guidelines 
on pregnancy in cardiac disease, which state that vaginal delivery 
is almost always the preferred option—excluding a few severe 
diseases, which do not include CoA.5 Planned caesarean sections 
in women with cardiac disease such as CoA offer no maternal 
advantage while they increase adverse fetal outcome.5 24
We also found a surprisingly low rate (3.3%) of congenital 
heart disease in the offspring, considering that the recurrence 
risk is 4%–6.5% for non- syndromic maternal CoA and higher 
for syndromic CoA.25 One may speculate that isolated bicuspid 
valves in the offspring has been underdiagnosed, as there was 
no systematic echocardiographic screening of the neonates. The 
negative effect of beta- blockers on fetal birth weight did not 
reach statistical significance in our cohort, despite clear evidence 
for this association in both the general population and in women 
with cardiac disease.26–28
Limitations
This study has some limitations due to the nature of the obser-
vational data. The ROPAC provides data on individual pregnan-
cies and does not allow identification of the number of women 
having multiple pregnancies. As the ROPAC was designed to be 
applicable for all types of structural heart disease, CoA- specific 
parameters such as peak gradients across the coarctation or the 
prevalence of recoarctation were not included. The registry 
includes no specification for indication of prepregnancy medica-
tion. Particularly in unrepaired CoA or in women with re- coarc-
tation, information on the severity of the coarctation would be 
of importance for the generalisability of the results. Notable is 
the limited prevalence of pre- existing hypertension or antihy-
pertensive medication use in the unrepaired CoA group, which 
suggests that this cohort mainly involves mild unrepaired CoA 
or pseudocoarctation. Clinical details such as blood pressure 
difference between upper and lower extremities or variables 
of heart failure such as biomarkers were also not available. 
Although the sample size of this study is large compared with 
the literature, the number of events is low, which prevented a 
multivariate analysis of risk factors and should be considered in 
the interpretation of the study results including the univariate 
analyses.
Figure 3 Univariate regression analysis, identifying predictors of hypertensive complications in pregnancy. Asterisk (*) denotes statistical 
significance. BMI, body mass index (kg/m2); CoA, aortic coarctation; HT, hypertensive disorder; LVEF, left ventricular ejection fraction; n.a., not 
available; NYHA, New York Heart Association.
Table 4 Cardiac and hypertensive complications stratified according 
to CoA characteristics
0
n=204
1
n=89
2
n=10 P value
MACE 9 (4.4) 3 (3.4) 1 (10.0) 0.611
Hypertensive disorders 8 (3.9) 8 (9) 0 (0) 0.153
P value was calculated between the risk categories, using a χ2 test.
0=no prior hypertension and repaired coarctation; 1=prior hypertension or 
unrepaired coarctation; 2=prior hypertension and unrepaired coarctation.
CoA, aortic coarctation; MACE, major adverse cardiac event.
Figure 4 Summarising figure of pregnancy outcomes in women with 
aortic coarctation. AF, atrial fibrillation; HF, heart failure; MACE, major 
adverse cardiac event (defined as maternal cardiac death, heart failure, 
atrial fibrillation or flutter, ventricular tachyarrhythmia, endocarditis, 
thromboembolic events, aortic dissection and acute coronary syndrome).
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CONCLUSION
In this prospective observational study of 303 pregnancies 
in women with aortic coarctation, MACE were rare and no 
maternal deaths or aortic dissections occurred. Univariable asso-
ciations with MACE are prepregnancy clinical signs of heart 
failure, LVEF <40%, NYHA class >1, cardiac medication use 
before pregnancy and hailing from an emerging country. Hyper-
tensive disorders of pregnancy are not more prevalent than in 
the general population. Although only a limited amount of data 
are available with few end points, these findings suggest preg-
nancy in women with CoA to be more safe and better tolerated 
than previously appreciated.
Key questions
What is already known on this subject?
 ► Aortic coarctation is a common congenital heart defect and 
considered a high- risk condition.
 ► Pregnancy is currently classified as modified WHO risk class 
II–III, which corresponds to an expected maternal cardiac 
event rate of 10%–19%, and hypertensive disorders of 
pregnancy are reported in 13%–30%; however, pregnancy 
outcomes have only been studied in small retrospective 
cohorts and clinical guidelines are mainly based on expert 
opinion.
What might this study add?
 ► This study of 303 pregnant women with aortic coarctation 
is based on data from a prospective registry and exceeds 
the numbers of patients in previous studies, making it an 
important contribution to the current literature.
 ► We found pregnancy to be better tolerated than previously 
thought, with a maternal cardiac event rate of 4.3% and 
hypertensive disorders of pregnancy occurring in 5.3%, the 
latter does not exceed the average in the general population.
 ► Even women with unrepaired coarctation do not have 
increased adverse cardiac, obstetric and fetal outcomes.
How might this impact on clinical practice?
 ► The data from this prospective observational study on 
pregnancies in women with aortic coarctation show that 
major adverse cardiac events are rare and hypertensive 
disorders of pregnancy are not more prevalent than in the 
general population.
 ► This suggests that women with aortic coarctation without 
risk factors can safely embark on pregnancy and should be 
counselled accordingly.
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